期刊
JOURNAL OF RHEUMATOLOGY
卷 39, 期 10, 页码 2008-2011出版社
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.111549
关键词
ADULT-ONSET STILL'S DISEASE; ANAKINRA; INTERLEUKIN 1; RANDOMIZED; MULTICENTER; WISSLER'S SYNDROME
类别
资金
- Biovitrum AB
Objective. To study the efficacy of anakinra versus disease-modifying antirheumatic drugs (DMARD) in refractory adult-onset Still's disease (AOSD). Methods. In a 24-week study, 22 patients with AOSD taking prednisolone >= 10 mg/day received anakinra (n = 12) or DMARD (n = 10). The primary endpoint was achievement of remission. Results. At 8 and 24 weeks, 7/12 and 6/12 receiving anakinra and 5/10 and 2/10 receiving DMARD achieved remission. Anakinra induced greater improvement in physical health measured by Medical Outcomes Study Short-Form 36 (SF-36; p < 0.011). During an open-label extension (OLE) of 28 weeks, 7/14 patients taking anakinra and 2/3 taking DMARD were in remission. Conclusion. Anakinra induced more beneficial responses than DMARD in patients with AOSD and was favored in the OLE phase. (ClinicalTrials.gov Protocol Registration NCT01033656). (First Release Aug 1 2012; J Rheumatol 2012;39:2008-11; doi:10.3899/jrheum.111549)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据